Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in chronic HBV/HDV co-infection in Caucasian patients

被引：0
|
作者：
Bazinet, Michel [1 ]
Pantea, Victor [2 ]
Cebotarescu, Valentin [2 ]
Cojuhari, Lilia [3 ]
Jimbei, Paulina [3 ]
Albrecht, Jeffrey [4 ]
Schmid, Peter [4 ]
Karimzadeh, Hadi [5 ]
Roggendorf, Michael [5 ]
Vaillant, Andrew [1 ]
机构：
[1] Replicor Inc, Montreal, PQ, Canada
[2] N Testemitanu State Univ Med & Pharm, Kishinev, Moldova
[3] Toma Ciorba Infect Clin Hosp, Kishinev, Moldova
[4] Natl Inst Genet, Los Angeles, CA USA
[5] Tech Univ Munich, Inst Virol, D-80290 Munich, Germany
来源：
HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
31
引用
收藏
页码：222A / 222A
页数：1
相关论文
共 50 条
  • [1] UPDATE ON THE SAFETY AND EFFICACY OF REP 2139 MONOTHERAPY AND SUBSEQUENT COMBINATION THERAPY WITH PEGYLATED INTERFERON ALPHA-2A IN CAUCASIAN PATIENTS WITH CHRONIC HBV/HDV CO-INFECTION
    Bazinet, M.
    Pantea, V.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Albrecht, J.
    Schmid, P.
    Krawczyk, A.
    Karimzadeh, H.
    Roggendorf, M.
    Vaillant, A.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S584 - S585
  • [2] REP 2139 monotherapy and combination therapy with pegylated interferon: safety and potent reduction of HBsAg and HDV RNA in Caucasian Patients with chronic HBV/HDV co-infection
    Bazinet, M.
    Pantea, V.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Vaillant, A.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 : 5 - 6
  • [3] Initial Follow Up Results from the REP 301 Trial: Safety and Efficacy of REP 2139-Ca and Pegylated Interferon Alpha-2a in Caucasian Patients with Chronic HBV / HDV Co-infection
    Bazinet, Michel
    Pantea, Victor
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Paulina
    Albrecht, Jeffrey
    Schmid, Peter
    Krawczyk, Adalbert
    Karimzadeh, Hadi
    Roggendorf, Michael
    Valliant, Andrew
    HEPATOLOGY, 2016, 64 : 912A - 912A
  • [4] One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection
    Bazinet, M.
    Pantea, V.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Krawczyk, A.
    Vaillant, A.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S96 - S97
  • [5] Update on safety and efficacy in the REP 401 protocol: REP 2139-Mgor REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naive caucasian patients with chronic HBeAg negative HBV infection
    Bazinet, M.
    Pantea, V.
    Placinta, G.
    Moscalu, I.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Iarovoi, L.
    Smesnoi, V.
    Musteata, T.
    Jucov, A.
    Krawczyk, A.
    Vaillant, A.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S256 - S257
  • [6] ONGOING ANALYSIS OF FUNCTIONAL CONTROL / CURE OF HBV AND HDV INFECTION FOLLOWING REP 2139-CA AND PEGYLATED INTERFERON ALPHA-2a THERAPY IN PATIENTS WITH CHRONIC HBV / HDV CO-INFECTION: 3-YEAR FOLLOW-UP RESULTS FROM THE REP 301-LTF STUDY
    Bazinet, Michel
    Pantea, Victor
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Pavlina
    Krawczyk, Adalbert
    Dittmer, Ulf
    Vaillant, Andrew
    HEPATOLOGY, 2019, 70 : 440A - 440A
  • [7] SIGNIFICANT REDUCTION OF HBsAg AND HDVRNA BY THE NUCLEIC ACID POLYMER REP 2139 IN CAUCASIAN PATIENTS WITH CHRONIC HBV/HDV CO-INFECTION
    Bazinet, M.
    Pantea, V.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Vaillant, A.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S257 - S258
  • [8] Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results from the REP 301-LTF study
    Bazinet, M.
    Pantea, V.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Vaillant, A.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S509 - S509
  • [9] Preliminary safety and efficacy of REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated interferon alpha 2a in treatment naive Caucasian patients with chronic HBeAg negative HBV infection
    Bazinet, Michel
    Pantea, Victor
    Placinta, Gheorghe
    Moscalu, Iurie
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Paulina
    Iarovoi, Liviu
    Smesnoi, Valentina
    Musteata, Tatiana
    Jucov, Alina
    Krawczyk, Adalbert
    Vaillant, Andrew
    HEPATOLOGY, 2016, 64 (06) : 1122A - 1123A
  • [10] Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naive to Nucleos(t)ide Therapy
    Bazinet, Michel
    Pantea, Victor
    Placinta, Gheorghe
    Moscalu, Iurie
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Pavlina
    Iarovoi, Liviu
    Smesnoi, Valentina
    Musteata, Tatiana
    Jucov, Alina
    Dittmer, Ulf
    Krawczyk, Adalbert
    Vaillant, Andrew
    GASTROENTEROLOGY, 2020, 158 (08) : 2180 - 2194
12345